The abstract is read at the publisher; the summary is JClub's.
Over 60 years, adenine nucleoside and nucleotide analogs have yielded multiple FDA-approved antivirals, including broad-spectrum agents like remdesivir, targeting viral DNA/RNA synthesis.
- Why it matters: Major viral outbreaks and pandemics, from HIV and hepatitis viruses to SARS-CoV, MERS-CoV, and SARS-CoV-2, create urgent needs for effective therapeutic options.
- What they did: This review traces adenine nucleoside/nucleotide analog antiviral mechanisms across the viral life cycle, highlighting representative potent small-molecule scaffolds, clinical development, combination strategies, and adenosine-based modification approaches.
- The result: The synthesis of past progress and current challenges aims to guide future antiviral nucleoside/nucleotide development, including repurposing efforts and opportunities in biology and chemistry.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.